Member Info for Thelix

Is reg pathways. FDA said do the trial and they are happy. They should just do the trial -if it means commercialising GI safety NSAID's. Faster release is pointless NSAID market is saturated. The GI safety claim was its ace up the sleeve.

A nice sideline into vet medicine as their is less reg pathways. OXP have now come under fire from MHRA too now. Why bother attempting Europe? They have tougher regs than MHRA. This is why I kept saying they should just do the trial to support GI safety claim. Still life yet though, and development suspended so less outgoings. They want to focus on these products. Should lift SP a bit maybe but doubt we'll see 2.5p+. Few weeks to get more news. Might get a mad scramble for these shares and see the same excitement as before.

AGQ took years to get data on silver literally lying on topsoil. This is a stitch up outfit.

how the SP can rise so well when someone bigger than the pi's can profit from it. Watch it walked down to 110p again - probably lower

Back down to the price it had for years.

I have worked in pharma for 10 years nearly. I know what it needs and the amount of staff and time required. I knew plenty about the company BH but not that employee count. Let me put this into perspective for you. Outsourcing is a lot more expensive, and not everything can be outsourced. The company has a commercial director before phase 2 trials have even completed. A commercial director in pharma shows the company wants to platform the drug itself. But they are outsourcing everything. They have absolutely no idea what they are doing. As to buying into what the big boys paid into -many made that mistake with woodford and OXP -myself included. Most pharmas fail, only 5 out of 1000 compounds pass phase 3. But the rewards are huge as new drugs yield billions in revenue. My reason for buying here was the clinical data was impressive and when they said they would launch on NASDAQ I saw an opportunity. what I DIDNT know is they would procrastinate and give mates rates leading to easily 2x more dilution than necessary, and essentially a shell outsourcing all of its scientific endeavours. This will be chugging through money like mad, and will need more funds once phase 2 completes.

The reasons for end of play. 1. I had a busy work day today 2. I wanted to give some the opportunity to spot it themselves. No insidious reasons.

We have a phase 2 first in class compound. The company has 7 employees. It really is a shell R&D setup. I work in pharma - You need a good 60-70+to support a compound through phase 2. The only way to explain otherwise is they have outsourced a LOT of the work and are absolutely reliant on gaining partners. This is why I feel the price has dipped as cash levels recede from a lot of outsourcing. Phase 2 will need clinical manufacture and stability labwork, alongside a host of other duties 7 people cannot do. I was under the impression VRP were a small company - not a shell with some heads and outsourcing everything. Maybe that data is outdated, but theres a reason pharma usually has 500+staff (not in one timeframe necessarily) on one project by time it is commercial level. You may think it is insignifcant but I know the hurdles in this game and it is looking much less complete than I initially realised. Just my 2.

I will state what it is end of play tomorrow - but feel we can all learn by being able to research better so hawkeye that link. It isnt absolute nail in coffin, but it is pretty bad...

https://markets.ft.com/data/equities/tearsheet/profile?s=VRP:LSE What should a Phase 2 first in class compound need for commercial readiness etc or at least Ph3 readiness. Maybe it is old data from the company or maybe they are only counting certain levels but there is a number that will make you go "ah s***". Soon as I saw that I sold most of my holding. Also explains the lack of NASDAQ boost.

I sold most of my shares at the 130 sp...The answer is out there why this is dipping. I didnt realise when I first invested but a particular bit of info is out there.

Is based on cash and proprietal worth. I would wager a guess VRP have let go of some cash for clinical purposes or expansion purposes which causes a sudden downward blip.

on commercial partners. They have a set of drugs they want to market in a particular way. No partner =very bad times Finds a partner = good spike followed by reasonable growth in SP. They will be at the negotiating table until a negotiation has completed so impossible to establish timelines

Actually in a free ride in here as managed to buy in low and sold near that 1.2p mark a few months back. Merely calling a spade a spade. This has gone from 5.3p to 5.6p and people are commenting how this has so much momentum lol.

Unless the grades are bad, or another placement, or any other useless directorate related issues.

Or just someone with more money than sense. Nobody rational would put 174k into this dire share.

Congrats on buying UKOG at the correct time. Pure luck I would say given the volatility but there we go.

400% for most holders to break even....

LEG now has no money so Zaf will want his salary so placement round the corner. And VS made a loss even with all its contracts. This will go down.

are actually pretty poor compared to the other lithium AIM penny stocks....